Hide
Brief description of measure
CMS22: Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented:
Percentage of patient visits for patients aged 18 years and older seen during the measurement period who were screened for high blood pressure AND a recommended follow-up plan is documented, as indicated, if blood pressure is elevated or hypertensive.
Description of issue
The 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure guidelines include a recommendation regarding the use of blood pressure lowering medications for secondary prevention of cardiovascular disease in patients with a diagnosis of clinical ASCVD or estimated 10-year ASCVD risk of >= 10% where Stage 1 hypertension was indicated. The measure developer proposes adding the 2017 ACC/AHA recommendations in the Rationale section to allow providers to better identify appropriate treatment, but is not proposing updates to the logic to incorporate the recommendation.
The measure developer is specifically interested in the perspectives from the clinical community to evaluate the proposed text to include in the measure specifications.
Goal of review
Obtain clinical feedback
Show
Brief description of measure
CMS22: Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented:
Percentage of patient visits for patients aged 18 years and older seen during the measurement period who were screened for high blood pressure AND a recommended follow-up plan is documented, as indicated, if blood pressure is elevated or hypertensive.
Description of issue
The 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure guidelines include a recommendation regarding the use of blood pressure lowering medications for secondary prevention of cardiovascular disease in patients with a diagnosis of clinical ASCVD or estimated 10-year ASCVD risk of >= 10% where Stage 1 hypertension was indicated. The measure developer proposes adding the 2017 ACC/AHA recommendations in the Rationale section to allow providers to better identify appropriate treatment, but is not proposing updates to the logic to incorporate the recommendation.
The measure developer is specifically interested in the perspectives from the clinical community to evaluate the proposed text to include in the measure specifications.
Goal of review
Obtain clinical feedback